Dr. Quinn to front Boehringer European AFib awareness effort

Share this article:
Dr. Quinn to front Boehringer European AFib awareness effort
Dr. Quinn to front Boehringer European AFib awareness effort
Boehringer-Ingelheim has recruited actress Jane Seymour to serve as the face of a continental European atrial fibrillation and stroke awareness campaign.

The campaign, dubbed “1 Mission 1 Million: Getting to the Heart of Stroke,” will provide up to a million Euros for atrial fibrillation-related stroke education projects to be determined by a public vote. Visitors to heartofstroke.org can choose from among 184 projects in 36 countries to support. Boehringer, which makes Pradaxa, has lined up 40-plus third-party partners for the effort.

Like one in four adults over the age of 40, Seymour's mother had atrial fibrillation (AF) and she suffered a possibly-related stroke.

“Anyone who's been a caregiver for someone who's had a stroke will know how debilitating and horrendous strokes can be,” said Seymour in a statement. “There is an urgent need for people to learn more about AF and how it relates to stroke. Through 1 Mission 1 Million, the public can actively help to prevent one million AF-related strokes by doing something as simple as voting online.”

Seymour is an English actress probably best known for her roles as a Bond girl and as Dr. Quinn, Medicine Woman. In the US, Boehringer is running its Facing AFib awareness campaign featuring soap star Susan Lucci and her husband, Helmut Huber, who was diagnosed with atrial fibrillation in 1999.

In October, the FDA approved Boehringer's Pradaxa (dabigatran etexilate), a novel oral blood thinner, for stroke prevention in patients with atrial fibrillation. The drug, the first new blood thinner in 50 years, has been marketed in Europe since 2009.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...